Poised to launch its first marketing effort, Alnylam makes a big leap into CNS diseases and Alzheimer’s

With its lead RNAi drug poised for an historic approval, Alnylam $ALNY is now laying plans to create a pipeline of CNS drugs that will target some of the toughest diseases that face researchers today — including Alzheimer’s, the Night King of diseases.